Literature DB >> 26100271

Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?

Martha R Neagu1, David A Reardon1.   

Abstract

Entities:  

Keywords:  bevacizumab; epidermal growth factor receptor variant III; glioblastoma; rindopepimut; vaccine

Mesh：

Substances：

Year:  2015        PMID： 26100271     DOI： 10.2217/imt.15.39

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  6 in total

Review 1.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

2.  Extract of Herba Anthrisci cerefolii: Chemical Profiling and Insights into Its Anti-Glioblastoma and Antimicrobial Mechanism of Actions.

Authors:  Dejan Stojković; Danijela Drakulić; Marija Schwirtlich; Nemanja Rajčević; Milena Stevanović; Marina D Soković; Uroš Gašić
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-12

Review 3.  Cell-based immunotherapy of glioblastoma multiforme.

Authors:  Igor Bryukhovetskiy
Journal:  Oncol Lett       Date:  2022-02-23       Impact factor: 2.967

Review 4.  Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.

Authors:  Kelly M Hotchkiss; John H Sampson
Journal:  J Neurooncol       Date:  2020-08-19       Impact factor: 4.130

Review 5.  An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Authors:  Martha R Neagu; David A Reardon
Journal:  Curr Treat Options Oncol       Date:  2015-11

Review 6.  Glioblastoma under Siege: An Overview of Current Therapeutic Strategies.

Authors:  Mayra Paolillo; Cinzia Boselli; Sergio Schinelli
Journal:  Brain Sci       Date:  2018-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.